2019
DOI: 10.31640/jvd.5-6.2019(4)
|View full text |Cite
|
Sign up to set email alerts
|

PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer

Abstract: Lung cancer is one of the main causes of death from malignant neoplasm all around the world. For the purpose of personalized treatment immunohistochemical determination of specific proteins (biomarkers) presence in tissues and biological fluids is needed. Today management of patients with lung cancer is directly associated with determination of genes mutations: EGFR, ALK, ROS1 and rate of PD-L1 receptors expression. Depending on the PD-L1 expression level blockers of these receptors can be used as the first, s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 15 publications
(13 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?